CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for XenaCare Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

XenaCare Holdings, Inc.
14000 S Military Trl Ste 104
Phone: (561) 496-6676p:561 496-6676 DELRAY BEACH, FL  33484-2600  United States Fax: (561) 998-8182f:561 998-8182
On 7/24/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of XenaCare Holdings, Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
XenaCare Holdings, Inc. (XenaCare) markets and distributes a line of clinical and life style performance, homeopathic medications and nutrition supplement products (NSPs). The Company also markets the SunPill, which was developed to protect the skin when exposed to damaging ultraviolet rays. Its clinical products group includes its formulations - XenaCor, XenaTri and XenaZyme Plus. XenaCare’s products groups have been established to formulate a line of NSPs to be sold through direct response, catalog, mass media (radio and television) magazine advertising, Web sales, mass food and drug retailers and other channels of distribution. In May, 2009, NutraPharma, Inc. awarded to XenaCare the United States marketing rights to Cobroxin. In May, 2009, Mineral Sciences, Inc. awarded XenaCare the license to market and distribute a cellular cleanse at retail and detoxification product called Zeolite for retail distribution designed as a solution for removing heavy metals and toxins from the body.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201112/31/2010YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer FrankRizzo 56 2/1/2006
Chief Financial Officer, Director Bobby E.Story 69 4/1/2006 4/1/2006
Director Carlos J.Bonilla 3/24/2011 3/24/2011
Director AlanXenakis 61

Business Names
Business Name
EstraPet
Global International US, Inc.
XenaCare Holdings Inc.
4 additional Business Names available in full report.

General Information
Stock Exchange: OTC
Federal Tax Id: 203075747
Fax Number: (561) 998-8182


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023